Terms ending in 2033
Every in-force patent on Cellectis's record whose computed term ends in 2033, whoever holds it now. Soonest term end first, then patent number.
| Patent | Title | Holder | Status | Expires | Confidence |
|---|---|---|---|---|---|
| US 10,342,829 | Multi-Chain Chimeric Antigen Receptor and Uses Thereof In force · Medium confidence | Cellectis | In force | Medium confidence | |
| US 10,517,896 | Use of Pre T Alpha or Functional Variant Thereof for Expanding TCR Alpha Deficient T Cells In force · Low confidence | Cellectis | In force | Low confidence | |
| US 10,874,693 | CD19 Specific Chimeric Antigen Receptor and Uses Thereof In force · Medium confidence | Cellectis | In force | Medium confidence | |
| US 11,007,224 | CD19 Specific Chimeric Antigen Receptor and Uses Thereof In force · Low confidence | Cellectis | In force | Low confidence | |
| US 11,077,144 | CD19 Specific Chimeric Antigen Receptor and Uses Thereof In force · High confidence | Cellectis | In force | High confidence | |
| US 11,274,316 | Use of Pre T Alpha or Functional Variant Thereof for Expanding TCR Alpha Deficient T Cells In force · Low confidence | Cellectis | In force | Low confidence | |
| US 11,304,975 | Methods for Engineering Allogeneic and Highly Active T Cell for Immunotheraphy In force · Low confidence | Cellectis | In force | Low confidence | |
| US 11,311,575 | Methods for Engineering Highly Active T Cell for Immunotheraphy In force · Low confidence | Cellectis | In force | Low confidence | |
| US 11,414,674 | Use of Pre T Alpha or Functional Variant Thereof for Expanding TCR Alpha Deficient T Cells In force · Low confidence | Cellectis | In force | Low confidence | |
| US 11,891,614 | Methods for Engineering Allogeneic and Immunosuppressive Resistant T Cell for Immunotherapy In force · Medium confidence | Cellectis | In force | Medium confidence | |
| 9 more term ends in 2033 · Pro | |||||
10 of 19 patents shown. Soonest term end first, then patent number.
Pro members see all 19.
Updated Nov 15, 2026 · includes USPTO assignment & status data published Nov 15, 2026 and grant & fee data published Nov 10, 2026 (weekly) · how we know
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.